Evaluation of Heuron CTA for Detecting Suspected Large Vessel Occlusion Using Brain CT Angiography
A Single-Center, Evaluator-Blinded, Retrospective, Pivotal Clinical Trial to Evaluate the Efficacy of Heuron CTA, a Brain Image Detection and Diagnostic Support Software, for Assessing Suspected Large Vessel Occlusion Using Brain CT Angiography
2 other identifiers
observational
270
1 country
1
Brief Summary
This study evaluates Heuron CTA, a software that helps doctors detect blockages in brain blood vessels using CT angiography images. The software's results will be compared with diagnoses made by medical specialists to assess its accuracy. If it performs well, it may help doctors diagnose these conditions more quickly and effectively.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 21, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 21, 2024
CompletedFirst Submitted
Initial submission to the registry
April 15, 2026
CompletedFirst Posted
Study publicly available on registry
April 22, 2026
CompletedApril 22, 2026
April 1, 2026
8 months
April 15, 2026
April 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sensitivity and specificity of Heuron CTA in determining the presence of suspected large vessel occlusion
Sensitivity and specificity of Heuron CTA in determining the presence of suspected large vessel occlusion were assessed by calculating their 95% confidence intervals (CIs) and determining whether the lower bound exceeded the clinical success criterion of 80%. The Clopper-Pearson confidence interval method12) was used to calculate the 95% CI.
Within 8 weeks after collecting data
Secondary Outcomes (3)
Accuracy, ROC Curve and AUC value for classifying suspected large vessel occlusion
Within 8 weeks after collecting data
Sensitivity of Heuron CTA in determining suspected large vessel occlusion for each occluded vessel
Within 8 weeks after collecting data
Sensitivity and specificity of Heuron CTA in determining suspected large vessel occlusion based on adjusted occlusion criteria
Within 8 weeks after collecting data
Study Arms (2)
Positive Group
Diagnosed with large vessel occlusion due to occlusion of the vessels between ICA and MCA-M1 after taking brain CTA images
Negative group
Diagnosed as either not having large vessel occlusion or as normal after brain CTA images
Interventions
This software automatically analyzes Computed Tomography Angiography (CTA) images to detect suspected large vessel occlusion, assisting surgeons in their diagnostic decisions
Eligibility Criteria
(1) Adults over 19 years old (2) Brain CTA images acquired (3) who confirmed with large vessel occlusion(positive group) or not large vessel occlusion or normal(negative group)
You may qualify if:
- Adults aged 19 years or older who visited the clinical trial institution for brain CTA images between January 2020 and May 2021, and from November 2021 until IRB approval
- Individuals classified into the positive or negative group based on the following criteria:
- Positive group: Diagnosed with large vessel occlusion due to occlusion of the vessels between ICA and MCA-M1 after taking brain CTA images -- Negative group: Diagnosed as either not having large vessel occlusion or as normal after brain CTA images
You may not qualify if:
- Cases with poor-quality or incomplete brain CTA images7)
- Cases where intracranial prosthetic implants (e.g., catheters, coils) were present
- Cases that were previously used for AI model training and internal validation
- Any other cases deemed unsuitable for participation in the clinical trial based on the investigator's judgment \* Specific reasons were recorded in the case report form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Heuron Inc.lead
Study Sites (1)
Gachon University Gil Medical Center
Incheon, Namdong-gu, 21565, South Korea
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 15, 2026
First Posted
April 22, 2026
Study Start
February 28, 2024
Primary Completion
October 21, 2024
Study Completion
October 21, 2024
Last Updated
April 22, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share